Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Kaohsiung J Med Sci ; 39(6): 637-643, 2023 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-36916244

RESUMEN

In recent years, optical coherence tomography (OCT) biomarkers for specific retinal diseases have been found to be associated with treatment outcome and disease recurrence. The main purposes of this study were to identify OCT biomarkers for myopic choroidal neovascularization (mCNV) treated with intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF). OCT features in 43 eyes of 39 patients with mCNV treated with anti-VEGF with at least 1 year of follow-up were retrospectively analyzed. Eyes with subretinal hyperreflective material (SHM) in baseline spectral-domain OCT (SD-OCT) had significantly more visual improvement than eyes without SHM at month 6 (p = 0.007) and had a trend of more visual improvement than eyes without SHM (p = 0.058) at month 12. Eyes with subretinal fluid (SRF) at baseline had significantly more central retinal thickness (CRT) decrease than patients without SRF at month 6 and 12 (p = 0.012 and 0.006 respectively). In univariate regression analysis, dome-shaped macula (DSM), SRF in baseline OCT image and fuzzy border of mCNV when entering pro re nata (PRN) injection protocol tended to have higher risk of disease recurrence in 1 year (odds ratio: 14.86 (p = 0.003), 3.75 (p = 0.049) and 22.92 (p < 0.001) respectively). However, they were not significant in multivariate regression analysis. OCT biomarkers at baseline could provide prognostic information for mCNV management.


Asunto(s)
Neovascularización Coroidal , Miopía Degenerativa , Humanos , Inhibidores de la Angiogénesis/uso terapéutico , Factores de Crecimiento Endotelial/uso terapéutico , Factor A de Crecimiento Endotelial Vascular , Tomografía de Coherencia Óptica/métodos , Miopía Degenerativa/diagnóstico por imagen , Miopía Degenerativa/tratamiento farmacológico , Miopía Degenerativa/complicaciones , Estudios Retrospectivos , Agudeza Visual , Angiografía con Fluoresceína/métodos , Neovascularización Coroidal/diagnóstico por imagen , Neovascularización Coroidal/tratamiento farmacológico , Neovascularización Coroidal/complicaciones , Inyecciones Intravítreas , Biomarcadores
4.
Sci Rep ; 11(1): 19100, 2021 09 27.
Artículo en Inglés | MEDLINE | ID: mdl-34580364

RESUMEN

We aim to investigate the role of medication adherence history in treatment needed diabetic retinopathy (TNDR). We conducted a retrospective nested case-control study using 3 population-based databases in Taiwan. The major one was the 2-million-sample longitudinal health and welfare population-based database from 1997 to 2017, a nationally representative random sample of National Health Insurance Administration enrolled beneficiaries in 2010 (LHID2010). The national death registry and national cancer registry were also checked to verify the information. The outcome was defined as the TNDR. The Medication possession ratio (MPR) was defined as the ratio of total days of diabetes mellitus (DM) medication supply divided by total observation days. MPR ≥ 80% was proposed as good medication adherence. The association of MPR and the TNDR was analyzed. Other potential confounders and MPR ratio were also evaluated. A total of (n = 44,628) patients were enrolled. Younger aged, male sex and patients with less chronic illness complexity or less diabetes complication severity tend to have poorer medication adherence. Those with severe comorbidity or participating pay-for-performance program (P4P) revealed better adherence. No matter what the characteristics are, patients with good MPR showed a significantly lower likelihood of leading to TNDR after adjustment with other factors. The protection effect was consistent for up to 5 years. Good medication adherence significantly prevents treatment needed diabetic retinopathy. Hence, it is important to promote DM medication adherence to prevent risks of diabetic retinopathy progression, especially those who opt to have low medication adherence.


Asunto(s)
Retinopatía Diabética/tratamiento farmacológico , Cumplimiento de la Medicación/estadística & datos numéricos , Adulto , Anciano , Ceguera/epidemiología , Ceguera/prevención & control , Estudios de Casos y Controles , Retinopatía Diabética/diagnóstico , Femenino , Humanos , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Reembolso de Incentivo , Estudios Retrospectivos , Índice de Severidad de la Enfermedad , Taiwán , Resultado del Tratamiento , Baja Visión/epidemiología , Baja Visión/prevención & control , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA